Bio-Techne TECH Business Segments
| TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Diagnostics And Spatial Biology | $335.93M-1.1% | $339.57M-0.9% | $342.53M-1.1% | $346.26M-0.3% | $347.24M+0.5% | |
| Protein Sciences | $869.9M-0.2% | $871.43M+0.4% | $867.9M-0.3% | $870.24M+1.5% | $857.76M+1.6% | |
| Revenue by Product | ||||||
| Consumables | $977.32M0.0% | $977.77M+0.5% | $973.04M+0.1% | $972.29M+0.7% | $965.12M+1.2% | |
| Instruments | $108M+1.5% | $106.44M-1.2% | $107.71M-3.9% | $112.09M+1.6% | $110.28M-0.3% | |
| Royalty | $24.63M-0.3% | $24.7M+1.7% | $24.29M+2.5% | $23.69M+2.0% | $23.24M+1.5% | |
| Service | $100.86M-5.4% | $106.66M-4.5% | $111.7M+0.1% | $111.57M+1.3% | $110.13M+1.6% | |
| Revenue by Geography | ||||||
| APAC Excluding Greater China | $82.6M+0.7% | $82.02M+4.8% | $78.29M+1.3% | $77.26M-0.5% | $77.64M+4.0% | |
| CN | $104.06M+1.5% | $102.53M+1.6% | $100.93M+0.5% | $100.46M+3.1% | $97.48M-1.1% | |
| EMEA Excluding UK | $284.28M+2.5% | $277.33M+1.8% | $272.37M+2.3% | $266.31M+2.6% | $259.52M+2.4% | |
| GB | $56.61M+3.7% | $54.57M+0.9% | $54.09M-1.3% | $54.83M+5.8% | $51.8M-4.2% | |
| Rest Of World | $37.61M-3.6% | $39.02M+3.8% | $37.6M+0.1% | $37.55M-1.1% | $37.95M-3.6% | |
| US | $645.66M-2.2% | $660.11M-2.0% | $673.46M-1.4% | $683.23M-0.2% | $684.38M+1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Techne break its business down?
- Bio-Techne (TECH) reports revenue by business across 2 parts — Diagnostics And Spatial Biology and Protein Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Techne's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Techne's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
